Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Nasioudis D, Albright BB, Ko EM, Haggerty AF, Giuntoli RL 2nd, Burger RA, Morgan MA, Latif NA (2020) Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet 301(4):1047–1054

    CAS  Article  Google Scholar 

  2. 2.

    Babaier A, Ghatage P (2020) Mucinous cancer of the ovary: overview and current status. Diagnostics (Basel) 10(1):52

    CAS  Article  Google Scholar 

  3. 3.

    Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, De Hingh IH, Van Der Velden J, Arts HJ, Massuger LF et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240

    Article  Google Scholar 

  4. 4.

    Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B, Abboud K, Marolho C, The PSOGI Working Group et al (2018) Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 25:1668–1675

    Article  Google Scholar 

  5. 5.

    Farrell R (2019) Peritonectomy and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: what gynaecological oncologists really think. Aust N Z J Obstet Gynaecol 59(3):457–462

    Article  Google Scholar 

  6. 6.

    Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368–e377

    Article  Google Scholar 

  7. 7.

    Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA (2018) A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 150(1):23–30

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

All authors whose names appear on the submission: (1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; (2) drafted the work or revised it critically for important intellectual content; (3) approved the version to be published; and (4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Christos Iavazzo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iavazzo, C., Spiliotis, J. Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?. Arch Gynecol Obstet (2020). https://doi.org/10.1007/s00404-020-05636-w

Download citation